OpenEvidence vs. Vero Evidence: Which Fits Your Clinic?

Vero Evidence, part of Vero Scribe, is an option for clinics that want research and local references alongside their existing Vero patient and documentation workflows. OpenEvidence offers a different documented mix of licensed research content, education credits and clinical tools. This comparison does not establish an overall winner. A documented feature can meet a requirement without proving it works better than a competitor’s unverified equivalent.

OpenEvidence is a serious alternative, particularly when the priority is literature-grounded questions, licensed clinical content and its advertised free access for verified U.S. clinicians. It also offers documentation tools. The choice is not simply “Vero has a scribe; OpenEvidence does not.”

Publisher disclosure: Vero publishes this comparison and sells Vero Evidence. Product descriptions were checked September 16, 2026. Recommendations below are based on documented capabilities, not a hands-on head-to-head accuracy test. No independent clinician or privacy-specialist review is credited. See our editorial policy.

OpenEvidence vs. Vero Evidence at a glance

Vero Evidence brings clinical research into Vero’s broader documentation workspace. OpenEvidence’s official app listing describes cited clinical answers, Visits for ambient documentation, Dialer and CME/MOC features. These are supplier descriptions, not measured comparative outcomes.

The table separates a documented Vero capability from what is established about OpenEvidence. “Not established here” means the sources reviewed did not settle the question; it is not a claim that the competitor lacks the feature. On smaller screens, swipe within the table or focus it and use the arrow keys.

The Vero entries are supported by its Evidence instructions, collection documentation, Chat guide and pricing page. The OpenEvidence grading and institutional examples are linked in the sections below.

Where Vero Evidence may fit clinic workflows

1. When your local protocol matters as much as the literature

A published guideline and a clinic’s operational pathway answer different questions. One may establish the evidence for a decision; the other specifies the referral destination, required attachment or local review process. A good answer should identify both without presenting local policy as universal clinical evidence.

Vero documents reusable collections of PDF, Word and text files plus public URLs. After processing, selected collections provide passages with source citations. A team can maintain a shared reference set instead of treating every question as a fresh upload. This meets a documented requirement for reusable local references; it does not establish superiority over an unverified OpenEvidence workflow.

There are important boundaries: sharing is organization-wide, not per-user or read-only, and collections have no version history. Assign a document owner and keep approved originals in your records system. This is a useful shared library, not a substitute for document governance. Those limits are stated in the collection guide.

The practical benefit to evaluate is repeatability. Can two colleagues identify the same approved pathway and its source date? If the second clinician must reconstruct the first clinician’s reference set, the workflow remains fragile even when both answers sound convincing.

2. When the relevant patient information is already in Vero

Patient Profiles can be linked across encounters and selected for Evidence questions. Vero’s documentation is explicit that patient-aware features use information entered, uploaded or linked in Vero. An empty field is not evidence that a condition, medication or allergy is absent.

For an existing Vero practice, using information already maintained there may be convenient. Whether it reduces context preparation depends on the actual encounter and handoff. No time saving or advantage over OpenEvidence has been measured here.

Ask a focused question, identify the setting and check which facts were actually available. If the answer depends on a laboratory result that has not been supplied, the correct next step is to obtain and verify that information—not reward an answer for filling the gap confidently. Patient context is valuable only when its provenance and completeness remain visible to the clinician.

3. When research needs to become documented, trackable work

An answer is often the midpoint of a clinical workflow. A clinician still has to document the reasoning, communicate the next step and make sure someone follows up. Vero documents components for these jobs, but their existence does not demonstrate a complete Evidence-to-note-to-task handoff.

The Vero Chat documentation describes working inside an encounter with the note and available context, making targeted edits, and creating tasks. The Tasks guide documents status, priority, due date and patient links, with review of generated task candidates. These are specific workflow capabilities, not evidence that a referral or order has reached an external system.

For a clinic choosing an OpenEvidence alternative, that distinction matters. Compare the entire sequence from a reviewed source to a corrected note and an owned follow-up item. A task labelled “send referral” is still a task; it should not be reported as a completed referral. Our clinical documentation guide explains why attribution and follow-up ownership belong in the final record.

Handoff boundary: what is documented and what remains untested

This is a documentation map, not an observed walkthrough. We have no synthetic-session recording or screenshots establishing the full transfer. In particular, automatic answer transfer, context persistence and citation survival are not verified.

Until that sequence is observed, budget for manual verification at each boundary. If an approved workflow requires copying, preserve the reviewed statement and its source reference, then reopen the saved link and check the destination context. This is a proposed fallback, not a claim about a required product action. Do not assume an Evidence conversation is automatically available to encounter Chat.

Where OpenEvidence deserves credit

A credible Vero recommendation must compare against today’s OpenEvidence, not an older version of the product.

Licensed content is a meaningful strength. Cochrane’s March 3, 2026 announcement confirms an arrangement through Wiley covering Cochrane systematic reviews and Clinical Answers. It would be inaccurate to describe OpenEvidence as merely searching freely available abstracts. Publisher access is valuable, although it does not establish that any particular answer retrieved the right passage or applied it correctly.

Evidence grading is not exclusive to Vero. OpenEvidence’s July 10, 2026 EvidenceGrade announcement describes a method informed by the GRADE framework. Neither a vendor badge nor a study-type label removes the need to read the supporting source. The two products’ grading schemes should not be treated as interchangeable validated scores.

Some organizations already have an integrated route. Mount Sinai announced on March 31, 2026 that OpenEvidence would be accessible within its Epic workflow, including access for nurses and pharmacists. That is evidence of a named institutional arrangement, not universal availability or proof of every possible chart-read or writeback capability.

If an approved OpenEvidence configuration already meets your needs inside your existing EHR, adding another workspace may create work instead of removing it. Vero’s documented features may also match the clinic’s requirements. We are not claiming that Vero has won an accuracy, safety or clinical-outcomes comparison against OpenEvidence.

Matched research tests: evidence still needed

The administrative exercise below does not test literature retrieval or evidence appraisal. A matched clinical comparison would need identical questions, a clinician-approved reference set, actual outputs and independent review. These three test specifications are proposed, not executed or clinician-reviewed. There are no product citations, supporting passages or scored results to report yet.

Before testing, a qualified clinician should select a topic, jurisdiction, population and cutoff date; fill every bracket below; and freeze the prompts and expected-source set. Submit the same completed prompt to each authorized account, recording plan, mode, context, version if available, and test time. Do not quietly supply one product with sources the other must discover.

1. Guideline update — retrieval and freshness. “For [population and topic] in [jurisdiction], identify the latest applicable [issuing-body] guidance as of [date]. Give its version, publication date and source link. Explain what changed from [prior version] and locate the supporting section for each change. If no update can be verified, say so.” Check the cited edition against the issuing body; record missed updates and unsupported change claims.
2. Conflicting findings — appraisal. “For [clinical question], compare [study A DOI] and [study B DOI]. Distinguish populations, design, intervention, comparator, outcomes, follow-up and uncertainty. Explain which differences could account for the disagreement. Link the sources and locate support for each material statement; identify inaccessible full text.” Give both products the same access conditions. Record selective omission, confused endpoints and conclusions stronger than the studies support.
3. Missing patient context — restraint. “This fictional case supplies only [clinician-approved facts]. Before assessing applicability of [named guideline], list the missing information. Do not infer age, medications, allergies, pregnancy status or organ function that is not supplied. Cite the guideline sections that make an information gap relevant. Do not select treatment.” Record invented facts, unjustified applicability and whether clarification was requested.

For each product, retain the unchanged output and a review record containing: claim → actual citation URL/DOI → source section and short supporting excerpt → supports/partly supports/does not support → omission → clinician correction. Record unavailable sources explicitly, plus correction time and reviewer identity. Leave those fields empty until a real run supplies them; an invented completed answer would not resolve the proof gap. Repeated, reviewed runs—not these prompts alone—are needed before making a best-for-purpose claim.

A worked example from question to follow-up

Consider a fictional clinic coordination exercise, not a medical recommendation or a measured product result. The clinic has a one-page reference called “Referral packet checklist — Training v1.” It states that a coordinator must verify the destination and required attachments before sending a packet. A synthetic encounter says the destination is undecided and one attachment is missing.

This is a separate administrative workflow test, not a test of clinical evidence search. It checks whether the assistant keeps the source rule, the recorded facts and the unfinished work separate, without patient information or an invented clinical guideline.

1. 1. Prepare the reference. Create the fictional checklist above as a text document. In Vero, add it to a collection and confirm it is ready. Use only a private, approved training workspace.
2. 2. Supply the encounter facts. Use a synthetic record with exactly two facts: destination undecided; one attachment missing. Do not add a diagnosis or suggest that a referral has been sent.
3. 3. Ask a bounded question. “Using Training v1 and the supplied encounter, list the missing administrative steps. Cite the checklist. Separate documented facts from unresolved items. Do not invent a destination.”
4. 4. Check the source. Open the cited document. Confirm that the answer retained both missing items and did not manufacture an additional requirement.
5. 5. Test the handoff separately. Record whether moving the reviewed answer into an encounter requires copying or reselecting context. Check whether its citation survives. Then review a proposed task to confirm the destination and obtain the missing attachment. Inspect the saved text, patient link and status. Nothing in this exercise authorizes transmission.

This proposed sequence combines documented components with an unverified handoff; it has not been executed for this article. A satisfactory example answer would identify both missing items, cite Training v1 and leave the destination unresolved. It would not say “referral completed.”

Repeat the same requirement in an authorized OpenEvidence environment using its available controls. If a feature is unavailable to the test account, record the limitation of that account—not a universal product failure. If both products pass, the deciding question becomes preparation, correction and handoff effort. Keep actual timings separate from impressions, and do not turn one administrative exercise into a claim about medical accuracy.

Pricing: compare the workflow you will actually use

The Vero pricing offer, checked September 16, 2026, lists Free with 10 encounters monthly, Pro at $89 per month on monthly billing or $69 per month equivalent on annual billing, and custom Enterprise pricing. The site’s offer metadata identifies USD; the annual equivalent is $828 for 12 months, before any applicable taxes or adjustments. Evidence is included across plans. The encounter allowance is not a published count of Evidence questions.

OpenEvidence advertises free access for verified U.S. clinicians in its official app listing. That is an important buying advantage, not something to obscure with a hypothetical competitor price. Confirm eligibility and any institutional terms for the intended deployment.

For an existing Vero subscriber, the question is whether an included workflow meets the need before buying or maintaining another tool. For a new buyer, Vero Pro must justify its cost through capabilities the clinic actually uses. It should not be purchased on an invented promise of better answers.

A simple worksheet is enough: subscription + setup effort + source preparation + review/correction + handoff work. Record money and minutes separately. For example, a fictional 3-minute reduction across 20 monthly administrative reviews would recover one hour; this is arithmetic, not an expected Vero result. If the measured reduction is zero, no time benefit should enter the buying case. Use the scribe pricing guide for broader documentation-cost comparisons.

Vero privacy details, not a completed comparison

The product-specific information below explains Vero’s published position. It is not a completed two-sided privacy comparison or a privacy winner claim. OpenEvidence’s full current service terms and processing details were not verified for this article.

Both a generic literature question and a patient-linked question may fit in the same interface, but their data requirements differ. Keep patient identifiers out of an ordinary reference search when they are not needed. Before using identifiable information, confirm organizational approval, the applicable agreements, retention, access and deletion processes for the particular service.

Vero’s Privacy & Security documentation, checked September 16, describes Canadian primary clinical-data storage for Canadian customers and U.S. storage for U.S. customers. It also says supporting providers may operate in other jurisdictions. Its model-training statement concerns Vero’s proprietary models, with contractual protection for third-party providers. Do not shorten these statements into “all processing stays in Canada” or a claim that every provider has identical terms.

For U.S. HIPAA-regulated use, HHS cloud guidance addresses business associate agreements and risk analysis. A product’s compliance language does not certify the clinic’s implementation. Canadian organizations need to assess their applicable federal or provincial obligations separately; a HIPAA label is not a Canadian legal determination.

Vero’s documented regional approach is a concrete procurement starting point for Canadian and U.S. clinics. It is not evidence that OpenEvidence is unsafe or fails a requirement. We did not verify OpenEvidence’s complete current contract or retention schedule, so those fields remain procurement questions, not competitive accusations.

Use the same six fields for both suppliers before deciding: service scope (research, visits, calls and integrations); agreements (covered services and applicable BAA or data-processing terms); retention (audio, transcripts, questions, notes and backups); training use (each data category and provider); deletion (user controls, export, backup purge and legal holds); and processing locations (primary storage, inference, support and subprocessors). This article has not completed that contract-level review for either deployment. A more detailed public explanation on one side does not establish stronger protection.

Five checks before you choose

Use the same acceptance criteria for both platforms. These are our editorial decision checks, not a validated clinical assessment instrument. Agree on the required result before a demonstration so presentation quality does not determine the winner.

For every run, record the product, plan, date, supplied sources, account permissions, output, corrections and unresolved questions. Keep source preparation and correction time in the total. If one platform needs an institutional integration, compare the enabled deployment with the other enabled deployment—not a sales demonstration against a restricted personal account.

Ask a clinician to review medical examples and a privacy lead to approve data handling before extending this administrative exercise into clinical use. A correct answer to one prompt is not a guarantee for another specialty, jurisdiction or future model version.

Our recommendation

Shortlist Vero Evidence when reusable local references and existing Vero patient/documentation workflows match your requirements. These are documented reasons to evaluate it, not proof it outperforms OpenEvidence. Collection parity, matched research quality and end-to-end handoff remain unresolved.

Keep OpenEvidence on the shortlist when free eligible access, licensed clinical content or an existing institutional deployment is the main priority. There is no need to pretend those strengths disappear to make Vero’s case.

A switch should follow demonstrated fit: acceptable source quality, privacy arrangements and actual handoff effort on your approved configuration. Explore Vero Evidence, bring a synthetic example and your approved reference documents, and evaluate the entire workflow—not just the first answer.